Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3399 Target Snapshot

Sodium channel protein type 2 subunit alpha · SINGLE PROTEIN · Rattus norvegicus

185Compounds
34Assays
6Approved Drugs
138.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P04775. Use UniProt P04775 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P04775 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Sodium channel protein type 2 subunit alpha as ChEMBL target CHEMBL3399, mapped to UniProt P04775. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Sodium channel protein type 2 subunit alpha
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-13
ChEMBL target ID
CHEMBL3399
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P04775
Sodium channel protein type 2 subunit alpha
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Sodium channel protein type 2 subunit alpha is the right protein anchor across sources, using UniProt P04775 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSodium channel protein type 2 subunit alpha
UniProt AccessionP04775
Component TypeProtein
Sequence Length2005 aa

Sodium channel protein type 2 subunit alpha

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Sodium channel protein type 2 subunit alpha, mapped to UniProt P04775. Sequence length is 2005 aa.

Mapped IDP04775
Review nameSodium channel protein type 2 subunit alpha
OrganismRattus norvegicus
Clinical Profile

Clinical Phase Distribution

6
Approved
1
Phase III
5
Phase II
Assay Mix

Activity Type Distribution

IC50122.0
KI1.0
EC507.0
KD8.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3318149 8.55 IC50 2.8 Preclinical
CHEMBL525818 8.52 Kd 3.0 Preclinical
CHEMBL3318150 8.52 IC50 3.0 Preclinical
CHEMBL3318148 8.46 IC50 3.48 Preclinical
CHEMBL507974 8.4 IC50 4.0 Clinical
CHEMBL2402969 8.28 Kd 5.3 Preclinical
CHEMBL3318147 8.1 IC50 8.0 Preclinical
CHEMBL3318134 8.1 IC50 8.0 Preclinical
CHEMBL299668 8.05 Ki 9.0 Preclinical
CHEMBL3318136 7.62 IC50 24.0 Preclinical
Distribution

pChEMBL Value Distribution

18
5.0
20
5.5
25
6.0
11
6.5
14
7.0
4
7.5
7
8.0
3
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

MIBEFRADIL
CHEMBL45816
Approved 1997
PIMOZIDE
CHEMBL1423
Approved 1984
Assay Landscape

Assay Landscape

34
Total Assays
80
Tested Compounds
2
Assay Types
Binding — 30 assays, 80 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 27 78 6.2
single protein format 2 2 7.7
assay format 1 0
Functional — 4 assays, 44 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 7 6.7
assay format 1 19 6.0
tissue-based format 1 18 5.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine